RxDoctor Payments Data

Priyanka Singh, MD

Internal Medicine · Yardley, PANPI 1013112911

Payments from drug & device makers

$1,153in general payments, 2019–2025

Across 40 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$187
  • Amgen$160
  • Novo Nordisk$131
  • Eisai Inc.$124
  • Biohaven Pharmaceuticals, Inc.$121
  • Acclarent, Inc$113
  • plus $317 from 13 others

What the payments were for

  • Food & beverage$1,153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,153 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,445
Medicare patients
296
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$29,952
JanuviaSitagliptin Phosphate24$23,305
WegovySemaglutide14$21,144
EliquisApixaban23$20,318
FarxigaDapagliflozin Propanediol14$16,007
Janumet XrSitagliptin Phos/Metformin Hcl13$13,808
Praluent PenAlirocumab11$7,360
Breo ElliptaFluticasone/Vilanterol18$7,108
Spiriva HandihalerTiotropium Bromide11$5,512
BelsomraSuvorexant12$4,850
SynthroidLevothyroxine Sodium58$4,359
Rosuvastatin Calcium236$4,027
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,915
Levothyroxine Sodium195$2,948
Candesartan Cilexetil23$2,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$131$51,09646 claims
PfizerEliquis$34$20,31823 claims
GSKBreo Ellipta$29$7,10818 claims
AbbVieSynthroid$14$4,35958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Yardley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →